In their article, Richy et al1 declare "no relevant financial interest in this article." I note, however, that one of the key trials2 cited in their systematic review (reference 24) was by some of the same authors. The Lancet study was sponsored by Rotta Research Laboratorium, Milan, Italy, who markets their product as a medicinal agent in various European Union countries and may be seeking to market their product as a medicinal agent in the United Kingdom. Under these circumstances, it would seem appropriate for the authors to declare their connection with Rotta, at least in terms of previous funding.
Jobanputra P. Structural and Symptomatic Efficacy of Glucosamine and Chondroitin: Relevant Financial Interest?. Arch Intern Med. 2004;164(3):338-339. doi:10.1001/archinte.164.3.338-c